imatinib mesylate has been researched along with Duncan Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chinen, Y; Fujino, T; Horiike, S; Isa, R; Kawaji, Y; Kobayashi, T; Kohno, K; Kuroda, J; Kuwahara-Ota, S; Nakamura, S; Nishiyama, D; Shimura, Y; Tsukamoto, T; Yamaguchi, J | 1 |
| Bacigalupo, A; Bresciani, P; Cimminiello, M; Coluzzi, S; Corradini, P; Fedele, R; Gabrielli, A; Leoni, P; Mordini, N; Nuccorini, R; Olivieri, A; Olivieri, J; Onida, F; Pane, F; Pascale, S; Patriarca, F; Pavone, E; Poloni, A; Selleri, C; Svegliati, S | 1 |
| Bekkenk, MW; Jansen, PM; Meijer, CJ; Middeldorp, JM; Stevens, SJ; Vermeer, MH; Willemze, R | 1 |
| Cools, J | 1 |
| Cogan, E; Goldman, M; Roufosse, F | 1 |
| Belaud-Rotureau, MA; Bouabdallah, K; Fitoussi, O; Foucaud, C; Leguay, T; Marit, G; Milpied, N; Parrens, M; Pigneux, A; Tabrizi, R | 1 |
1 review(s) available for imatinib mesylate and Duncan Disease
| Article | Year |
|---|---|
Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; CD52 Antigen; Glucocorticoids; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interleukin-5; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2006 |
1 trial(s) available for imatinib mesylate and Duncan Disease
| Article | Year |
|---|---|
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Autoantibodies; Benzamides; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Lymphoproliferative Disorders; Male; Middle Aged; Monitoring, Physiologic; Myeloproliferative Disorders; Piperazines; Prednisolone; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Severity of Illness Index; Survival Rate; Time Factors | 2013 |
4 other study(ies) available for imatinib mesylate and Duncan Disease
| Article | Year |
|---|---|
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Lymphoproliferative Disorders; Male; Prednisone; Protein Kinase Inhibitors; Splenomegaly; Tomography, X-Ray Computed; Vincristine | 2019 |
EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.
Topics: Aged; B-Lymphocytes; Benzamides; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoproliferative Disorders; Neoplasms, Second Primary; Piperazines; Pyrimidines; Skin Neoplasms | 2003 |
The hypereosinophilic syndrome: idiopathic or not, that is the question.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets | 2005 |
EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kidney Medulla; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Lymphoproliferative Disorders; Middle Aged; Piperazines; Pyrimidines; Recurrence; Spleen; Translocation, Genetic | 2007 |